We report here the identification and characterization of a novel paired-like homeobox-containing gene (Ehox). This gene, identified in embryonic stem (ES) cells, is differentially expressed during in vitro ES cell differentiation. We have assessed Ehox function using the ES cell in vitro differentiation system. This has involved molecular and biological analyses of the effects of sense or antisense Ehox expression (using episomal vectors) on ES cell differentiation. Analysis of antisense Ehox-expressing ES cells indicates that they are unable to express marker genes associated with hematopoietic, endothelial, or cardiac differentiation following removal of leukemia inhibitory factor. In contrast, overexpression of Ehox using the sense construct accelerated the appearance of these differentiation markers. ES cell self-renewal and differentiation assays reveal that inhibition of Ehox activity results in the maintenance of a stem cell phenotype in limiting concentrations of leukemia inhibitory factor and the almost complete impairment of the cardiomyocyte differentiation capacity of these cells. We therefore conclude that Ehox is a novel homeobox-containing gene that is essential for the earliest stages of murine ES cell differentiation.
Murine embryonic stem (ES)1 cells are derived from the inner cell mass of the day 3.5 post coitus blastocyst and can be maintained in culture as a self-renewing totipotent population in the presence of the growth factor, leukemia inhibitory factor (LIF) (1, 2). These cells form the basis for much current murine transgenic and gene targeting technology (3) as they have the capacity to generate all tissues, including the germ line, when re-injected into the blastocyst (4, 5). ES cells can also differentiate in vitro into a wide range of cell types that are derived from all three embryological germ layers. These include hematopoietic lineages of mesodermal origin (6), neuronal cells of ectodermal origin (7), liver (8, 9) and pancreatic cell types derived from embryonic endoderm (10), as well as visceral and parietal extra-embryonic endoderm (11,12). With the isolation of human ES cells (13,14), it has been proposed that the in vitro differentiation capacity of these cells could be utilized for somatic cell therapy to treat a number of diseases (10,15,16). This technology, however, is severely limited by the heterogeneity of the differentiation process and by the limited molecular characterization of the system. A detailed analysis of the molecular mechanisms involved in the early differentiation steps may allow the development of lineage selection strategies (7) to generate therapeutic quantities of a specific cell type.One of the most closely studied differentiation pathways using the ES cell differentiation system has been the commitment to, and the differentiation of, hematopoietic stem cells (17-20). We have recently described the in vitro differentiation of ES cells, cultured as embryoid bodies (EBs), and the time course of commitment of these cells to the hemopoietic lineage (2...